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Mitochondrial disorders are genetically and clinically heterogeneous, mainly affecting
high energy-demanding organs due to impaired oxidative phosphorylation (OXPHOS).
Currently, effective treatments for OXPHOS defects, with complex I deficiency being the
most prevalent, are not available. Yet, clinical practice has shown that some complex I
deficient patients benefit from a high-fat or ketogenic diet, but it is unclear how these
therapeutic diets influence mitochondrial function and more importantly, which complex
I patients could benefit from such treatment. Dietary studies in a complex I deficient
patient with exercise intolerance showed increased muscle endurance on a high-fat
diet compared to a high-carbohydrate diet. We performed whole-exome sequencing to
characterize the genetic defect. A pathogenic homozygous p.G212V missense mutation
was identified in the TMEM126B gene, encoding an early assembly factor of complex
I. A complementation study in fibroblasts confirmed that the p.G212V mutation caused
the complex I deficiency. The mechanism turned out to be an incomplete assembly
of the peripheral arm of complex I, leading to a decrease in the amount of mature
complex I. The patient clinically improved on a high-fat diet, which was supported by
the 25% increase in maximal OXPHOS capacity in TMEM126B defective fibroblast by
the saturated fatty acid palmitic acid, whereas oleic acid did not have any effect in those
fibroblasts. Fibroblasts of other patients with a characterized complex I gene defect
were tested in the same way. Patient fibroblasts with complex I defects in NDUFS7
and NDUFAF5 responded to palmitic acid, whereas ACAD9, NDUFA12, and NDUFV2
defects were non-responding. Although the data are too limited to draw a definite
conclusion on the mechanism, there is a tendency that protein defects involved in early
assembly complexes, improve with palmitic acid, whereas proteins defects involved in
late assembly, do not. Our data show at a clinical and biochemical level that a high fat
diet can be beneficial for complex I patients and that our cell line assay will be an easy
tool for the selection of patients, who might potentially benefit from this therapeutic diet.
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INTRODUCTION
Mitochondrial disorders are genetically and clinically
heterogeneous metabolic disorders with a prevalence of ∼1
in 5,000 in the general population (Skladal et al., 2003; Gorman
et al., 2015). Especially high energy-demanding organs are
affected as a result of impaired oxidative phosphorylation
(OXPHOS), commonly manifesting with pronounced
neuromuscular symptoms, fatigability and exercise intolerance.
The subunits of the OXPHOS machinery are encoded by both
the nuclear and mitochondrial DNA and pathogenic mutations
in either genome can affect OXPHOS capacity, often presenting
with isolated or combined mitochondrial complex deficiencies.
Complex I deficiency (NADH: ubiquinone oxidoreductase) is
the most prevalent OXPHOS disorder and is found either in
isolation or combined with deficiencies of the other complexes
(McFarland et al., 2004). Treatment options in complex I
deficiencies are currently limited, despite extensive research on
a variety of approaches, and successes are often anecdotic and
not applicable to all patients. Clinical improvements as a result
of high-fat intake with or without carbohydrate restriction have
been reported for some of the complex I deficient patients and
have led to the prescription of high-fat and ketogenic diets to
patients with complex I, but also with pyruvate dehydrogenase
complex deficiencies, Leigh syndrome, epilepsy and Parkinson
disease (Wijburg et al., 1992; Roef et al., 2002; Kang et al.,
2007; Baranano and Hartman, 2008; Rogovik and Goldman,
2010; Paleologou et al., 2017; Sofou et al., 2017). The resulting
increase in plasma fatty acids and deprivation of carbohydrates
is expected to cause a shift from a glycolytic energy metabolism
to the beta-oxidation of fatty acids, which is accompanied by the
production of ketone bodies in the liver mitochondria (Peters
and Leblanc, 2004; Stanley et al., 2014; Paoli et al., 2015). Ketone
bodies (3-beta-hydroxybutyrate, acetoacetate, and acetone)
are short-chain organic acids that can freely diffuse across
cell membranes and were suggested to serve as an alternative
energy substrate to glucose for the brain (Hasselbalch et al.,
1995; Scholl-Burgi et al., 2015). The ketogenic diet was shown to
have beneficial effects for patients with pyruvate dehydrogenase
complex deficiency related brain pathology, especially in case
of pharmaco-resistant epilepsy (Sofou et al., 2017). Although
different mechanisms of action, involving both ketone bodies
and fatty acids, have been proposed (Schwartzkroin, 1999;
Fraser et al., 2003; Bough et al., 2006; Kim and Rho, 2008;
Xu et al., 2008; Maalouf et al., 2009; Jeong et al., 2011), the
precise mechanisms are not clear. Also for the treatment of
mitochondrial myopathies due to complex I deficiency the
therapeutic use of high-fat diets has been recommended, as
supplementation of fatty acids via direct triacylglycerol infusion
was shown to significantly improve exercise endurance in
some patients (Roef et al., 2002). The latter observation was
explained by an increase in mitochondrial beta-oxidation, which
results in relatively higher FADH2:NADH++H+ ratios than the
carbohydrate driven tricarboxylic acid cycle, thereby enabling
bypassing of the complex I defect (Roef et al., 2002; Paoli et al.,
2014; Steriade et al., 2014). Yet, this mechanism cannot by
itself explain why only some of the complex I deficient patients
respond to high-fat treatment, suggesting that these treatments
influence the OXPHOS system, at least in part, in a gene- or
protein-specific manner (Hughes et al., 2014; Frey et al., 2017).
Despite the clinical application of high-fat diets, it is
yet unknown which genetic complex I deficiencies could
benefit from these diets. In this paper, we characterize
the gene defect in a patient with complex I deficiency
using whole-exome sequencing, who clinically improved on
a high-fat diet. We tested the in vitro responsiveness to the
saturated fatty acid palmitic acid of this patient and other
patients with a genetically characterized complex I deficiency.
This simple in vitro assay could be used in a clinical
setting to select the patients who could benefit from this
treatment.
MATERIALS AND METHODS
Patient
A Dutch female patient, who has a healthy younger brother
and gave birth to a healthy child, was subject to HPLC based
metabolite profiling on blood-plasma and urine to reveal
metabolic abnormalities. A Quadriceps muscle biopsy was
taken to spectrophotometrically measure OXPHOS complex
activities for complex I, II+III, IV, and V, normalized to
citrate synthase activity, according to a method described by
Sgobbo et al. (2007). Muscle histochemistry was performed by
staining the succinate dehydrogenase (SDH) and cytochrome
oxidase (COX) complexes and electron microscopy was
performed to identify abnormalities in mitochondrial
morphology and quantity. A skin biopsy was taken from
the TMEM126B patient and dermal fibroblast were isolated
in a similar manner (as described below) as previously
executed for the five other patients with complex I deficiency
(NDUFS7, NDUFAF5, ACAD9, NDUFA12, NDUFV2 defective
fibroblasts), who were all biochemically and genetically
diagnosed at the Maastricht University Medical Centre
(MUMC+).
Dermal Fibroblast Sampling, Isolation
and Culturing
Primary dermal fibroblasts from the patient were obtained by
taking a 3–5 mm punch biopsy from the arm, which was cut
into 18 smaller pieces and 3 biopsy pieces were transferred to
each gelatin pre-coated 6-well containing Dulbecco’s Modified
Eagle Medium (DMEM, 25 mM glucose) supplemented with
20% fetal bovine serum (FBS). When reaching confluency,
fibroblasts were trypsinized and transferred to a T75 flask, and,
after 3 passages, immuno-stained to check HSP-47 positivity.
During later passages fibroblasts were cultured in DMEM
(25 mM glucose) supplemented with 10% FBS and 0.2%
Penicillin-Streptomycin.
Dietary Studies
The patient’s (TMEM126B patient) muscle endurance was
examined by performing a bicycle test at 15% of the
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maximal capacity (15% of Wmax), based on the patient’s
usual diet in which 34,5% of the energy was derived from
fat and 49,4% from carbo-hydrates. Magnetic Resonance
Phosphor Imaging (31P MRS) of the muscle was performed
to measure muscle recovery. A dietary intervention study
was performed, where the patient was first prescribed to
consume a high-carbohydrate diet for 3 weeks, where 25%
of the energy derived from fat, and subsequently a high fat-
diet, where 55% of the energy was derived from fat intake,
to study the effects of dietary intake on muscle endurance,
measured by the bicycle test at 15% of Wmax. Additionally,
differences in muscle endurance and strength were examined
with direct substrate infusion, comparing intra-lipid infusion
(3,7 mg/kg/min) to glucose infusion (10 mg/kg/min), and
measuring muscle strength at different body parts with intervals
of relaxation.
Whole-Exome Sequencing
Blood DNA was fragmented and exons were captured using
the Agilent SureSelect version 4, exome enrichment kit,
including UTRs (Agilent Technologies, Santa Clara, CA,
United States). Sequencing was performed on an Illumina
HiSeq2000 platform, using a 2 × 100 bp paired end setting
(Illumina, San Diego, CA, United States). Bcl2fastq 1.8.4 allowed
base-calling and demultiplexing; BWA 0.5.9 was used for read
alignment against human reference genome hg19. Duplicate
reads were removed by Picard software suite 1.77 (Broad
Institute); variant calling was performed with GATK 2.1-8
(Broad Institute). An in-house data analysis pipeline extracted
database information on annotated variants according to the
UCSC RefGene track; dbSNP137 and dbNSFP v2.0. Exome data
were filtered for homozygous and heterozygous variants with
allele frequencies lower than 1% (dbSNP137) and a coverage
of >10 reads, consisting of non-synonymous substitutions,
INDELs (in-frame and frameshift), nonsense mutations and
splice-variants. Non-annotated variants were maintained, unless
allele frequencies exceeded 5% in our in-house patient database.
Missense variants in moderately to highly conserved domains
were maintained. Pathogenicity of non-synonymous missense
mutation was estimated by Polymorphism Phenotyping-2
(PolyPhen-2), Sorting Intolerant From Tolerant (SIFT) and
PROVEAN.
Sanger Sequencing and QPCR
Mutation segregation analysis was performed on blood
DNA from the healthy mother and index patient. The
father was not available for further analysis. Primers
were designed to cover the exon 5 missense mutation in
TMEM126B (transmembrane protein 126B, NC_000011.10)
(Supplementary Table S2). The TMEM126B nDNA copy
number was quantified by the 7900HT Fast Real-Time PCR
System, normalizing to nuclear B2M (nuclear gene beta-2-
microglobulin, NC_000015.10). Primers were designed in exons
1, 2, and 5 (Supplementary Table S3) and amplification was
performed using Sensimix Sybr Hi-Rox (Bioline, Taunton, MA,
United States).
Blue Native-Polyacrylamide Gel
Electrophoresis
Mitoplasts were isolated from fibroblasts of the index patient,
control 1 (C1) fibroblasts, which were Normal Human Dermal
Fibroblasts (NHDF), control 2 (C2) fibroblasts derived from a
single healthy individual, and an NDUFA9 mutant as previously
described (Nijtmans et al., 2002). 25 µg mitoplast fraction was
loaded on a 4–16% polyacrylamide gradient gel (Invitrogen),
after quantification by Qubit Protein Assay Kit (Thermo Fisher
Scientific, Waltham, MA, United States). Western blot analysis
was performed by hybridization with monoclonal antibodies
for complex I subunit NDUFA5, NDUFB8 and complex II
(SDHA) as a protein loading control (Mitosciences, Eugene, OR,
United States).
Cloning and Lentiviral Complementation
TMEM126B cDNA (isoform A, NM_018480.4) was cloned
into a 3rd generation pUltra-Chili lentiviral backbone vector,
containing a tomato-red reporter gene for validating viral
transduction efficiency (Addgene, Malcolm Moore Lab). The
p.G212V mutation was introduced by side directed mutagenesis
according to the QuikChange II Site-Directed Mutagenesis
Kit (Agilent Technologies). Transfection of HEK293FT viral
producing cells was accomplished by combining transIT (Mirus
Bio), 3rd generation packaging and envelope plasmids (Rev, Gag
and Pol, VSV-G) and the backbone expression vector. 48 h post
transfection, media containing viral particles were collected and
filtered (0.45 µm), subsequently polybrene was added (8ug/ml).
Patient fibroblast were seeded at 30% confluency and transduced
for 24 h, resulting in a transduction efficiency of >90%.
Seahorse Analysis
Patient (TMEM126B) fibroblasts, control 1 (C1) fibroblasts,
which were Normal Human Dermal Fibroblasts (NHDF), and
control 2 (C2) fibroblasts, deriving from a single healthy
individual, were seeded at 22,000 cells per well, using 12 wells per
condition, and attached overnight in standard DMEM (25 mM
glucose) supplemented with FBS (10%). One hour prior to assay,
media was replaced with Seahorse assay media containing 10 mM
glucose, 2 mM glutamine, 1 mM pyruvate, 10% FBS, and oxygen
consumption rates (OCR) were measured using the Seahorse XF
Cell Mito Stress Test Kit and the Seahorse XFe96 device (Seahorse
Bioscience, North Billerica, MA, United States) according to the
manufacturer’s protocol.
To test the effect of free fatty acids (FFAs) on the
mitochondrial respiration in patient (TMEM126B, NDUFS7,
NDUFV2, NDUFA12, NDUFAF5) and control (C1) fibroblasts,
we seeded 12,000 fibroblasts per well, using eight replicate
wells per condition, in a Seahorse XF 96-well plate. Cells
attached overnight in normal DMEM (25 mM) growth media,
supplemented with 10% FBS. Prior to assay, fibroblasts were
incubated for 16 h in DMEM with glucose (25 mM), but with
limited FBS (1%), where either 500 µM BSA-conjugated palmitic
acid or oleic acid was added to the media of the treated conditions
and unbound BSA was added to the untreated conditions. FFAs
need to be BSA-conjugated (ratio FFA: BSA = 6:1) in order to be
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taken up by the cells. One hour before assay, media was replaced
with Seahorse assay media containing 10 mM glucose, 2 mM
glutamine, 1 mM pyruvate, 1% FBS, and OCR were measured
using the Mito Stress Kit according to the manufacturer’s manual.
Administration of oligomycin (2.0 µM) blocked complex V
activity, and was used as a measure for ATP production (start
resp. – oligomycin resp.). Uncoupling agent FCCP (1.0 µM)
stimulated cells to their maximal respiration level and was used
together with antimycin A/rotenone (0.5µM), blocking complete
OXPHOS respiration via complex I and III, as a measure
for maximal respiratory capacity (FCCP resp. – antimycin
A/rotenone resp.). Furthermore, OXPHOS spare capacity (FCCP
resp. – start resp.) and proton leak (oligmycin resp. – antimycin
A/rotenone resp.) were determined. OCR was measured at
four time points after compound administration, where the
4th measurement was used to calculate statistical significance
(P < 0.05). To correct for differences in proliferation rate, OCR’s
were normalized to control according to protein quantity.
Statistical Analysis
Statistical significance was calculated using a two-sample t-test,
one-tailed, equal variance. A 95% confidence interval and alpha-
level 0.05 was applied.
RESULTS
Patient Clinic and OXPHOS Complex I
Activity
A female from a non-consanguineous family had a motor
development delay from birth onward, while mental milestones
were reached in time. Muscle weakness and cramps in
the legs developed and she had difficulties with walking.
The muscle weakness could disappear after resting for
2 h. Exercise intolerance persisted, and at 14 years of age
metabolic investigations indicated elevated levels of lactic acid
(2.8–5 mmol/l). Alanine and pyruvic acid levels were normal.
Muscle histochemistry showed an increased intensity and linear
staining of SDH and COX in the subsarcolemmal regions.
Furthermore, ragged red fibers were seen in approximately 40%
of the muscle tissue. Electron microscopy indicated elongated,
enlarged and abnormally shaped mitochondria (subsarcolemmal)
and dispersed dense bodies with abnormal cristae and crystalline
inclusions (Supplementary Figure S1). Complex I activity of the
TABLE 1 | Oxidative phosphorylation (OXPHOS) complex activities in patient
muscle biopsy.
OXPHOS
complex
Activity Control SEM % as to
control SEM
I 0.76 (µmol NADH/min/g) 3.66 ± 0.22 21% (↓)
II n.d. (µmol INT+/min/g) 723 ± 40 n.d.
II+III 7.43 (µmol cyt c/min/g) 5.20 ± 0.32 143% (↑)
IV 195.0 (k/min/g) 94.6 ± 3.5 206% (↑)
V 31.20 (µmol Pi/min/g) 11.90 ± 0.83 262% (↑)
patient was approximately 20% of control muscle (Table 1) and
increased activities were measured for CIV and CV. For the last
10 years the patient remained easily fatigued.
Dietary Studies
Bicycle endurance testing (15% of Wmax) on the patient’s
(TMEM126B patient) usual diet indicated that muscle endurance
was far below normal levels, where the test persisted 60 min
with a mean oxygen consumption (VO2mean) of 7,45 ml/kg/min.
Also the maximal exertion (Wmax: 60 W) and maximal
oxygen consumption levels (VO2max: 13,0 ml/kg/min) were
below normal level and Magnetic Resonance Phosphor Imaging
(31P MRS) of the muscle showed delayed recovery of the
phosphocreatine levels after exercise. Dietary intervention studies
were performed to examine the effect of a high-carbohydrate
diet (25% of energy from fat) vs. a high fat-diet (55% of
energy from fat). During the 3 weeks of carbohydrate diet,
the patient felt increasingly exhausted and activities of daily
living were more difficult to perform than with her usual diet.
Exercise testing showed that the patient’s bicycle endurance
was 53% prolonged after the high-fat diet, compared to the
carbohydrate diet (95 min vs. 62min), where the mean oxygen
consumption was higher after the high-fat diet (VO2mean: 8,51
vs. 6,82 ml/kg/min). No differences were measured with the
maximal exertion test (Wmax), although oxygen consumption
was higher after the high-fat diet. Differences in endurance
measured after direct substrate infusion showed that the patient
sustained the bicycle test 38% longer (90 min vs. 65 min) on
intra-lipid infusion compared to glucose infusion. The mean
oxygen consumption (VO2mean) was higher with lipid infusion
than glucose infusion (7,45 ml/kg/min vs. 5,09 ml/kg/min). Also
in muscle strength, which was measured at different body parts,
lipid-infusion seemed to have an advantage in terms of strength
of the lower extremities, with less decline between subsequent
measurements. More subjective, the patient stated that she felt
physically better when consuming a high-fat diet (Supplementary
Table S1).
Whole-Exome Sequencing (WES)
Whole-exome sequencing analysis revealed a homozygous
c.635G > T missense mutation in the TMEM126B gene, a known
complex I assembly factor (NM_018480.4:c.635G > T, chr: 11,
g.85347215). The resulting p.G212V amino-acid substitution
is located in a transmembrane region at a position that is
highly conserved in mammals (Nextprot: NX_Q8IUX1). In
vertebrates, the conservation of Glycine, Serine, and Alanine
at p.212 (belonging to a class of small size amino acids)
suggested structural constraints on the size of the amino
acid, which is violated by substitution with a larger valine
residue. In silico pathogenicity predictions assigned highly
damaging properties to the mutation at protein level (SIFT:
0.002, PROVEAN:−6.2, PF: 0.99). Mutation segregation analysis
confirmed a recessive inheritance pattern as the mother was
heterozygous carrier (Supplementary Figure S2). No DNA
was available from the father and healthy brother, therefore
the possibility of a hemizygous mutation was excluded by
TMEM126B copy-number analysis (Supplementary Figure S3).
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The p.G212V mutation has an allele frequency of 0.1–0.2%
(dbSNP: rs141542003) in dbSNP and ExAC databases.
Complex I Assembly and Lentiviral
Complementation
The effect of the TMEM126B mutation on complex I
integrity was studied by Blue-Native PAGE electrophoresis.
Mitochondrial fractions were isolated from fibroblasts of the
patient (TMEM126B patient), two controls [control 1 (C1)
and control 2 (C2)] and an NDUFA9 mutant as a negative
control. Antibodies against the subcomplex Iα (Cx Iα) subunit
NDUFA5 were used to detect mature complex I and assembly
intermediates containing this peripheral arm module (Q module)
(Lazarou et al., 2009; Andrews et al., 2013; Rak and Rustin, 2014).
A drastic loss of mature complex I and accumulation of the
315 kDa intermediate was observed, indicating impaired
complex I assembly in the patient (Figure 1A). Antibodies
against the subcomplex Iβ (Cx Iβ) subunit NDUFB8 were used
to detect assembly stages of the membrane arm of complex
I (P module) (Lazarou et al., 2009; Mimaki et al., 2012), and
showed normal quantities of NDUFB8 in the mature complex
I (Figure 1B). Complex II (SDHA) was used as a protein
loading control. To provide evidence that defects in TMEM126B
cause incomplete assembly of the peripheral arm of complex
I, patient fibroblasts were rescued by lentiviral transduction
with wild-type TMEM126B (isoform A, NM_018480.4).
Blue-Native PAGE and immunoblotting with anti-NDUFA5
indicated that the amount of fully assembled complex I in
patient fibroblasts was largely restored upon complementation
(Figure 1C).
FIGURE 1 | Blue-Native PAGE on fibroblasts of the patient (TMEM126B patient), 2 controls [control 1 (C1), control 2 (C2)] and NDUFA9 mutant. (A) Anti-bodies
against NDUFA5 were used to detect mature complex I and assembly intermediates containing the Q module of the peripheral arm of complex I (Cx Iα). A loss of
mature complex I and accumulation of the 315 kDa intermediate in the patient indicated impaired complex I assembly. (B) NDUFB8 antibodies detected assembly
stages of the membrane arm of complex I (Cx Iβ), which showed normal NDUFB8 quantities in mature complex I, suggesting that assembly of the membrane arm
(P-module) succeeded despite missing parts of the peripheral matrix arm [(A,B) are the representatives of two replicates]. (C) Patient fibroblasts (TMEM126B patient)
were lentiviral transduced with wild-type TMEM126B (TMEM126B patient + WT TMEM126B) and showed a recovery of the amount of mature complex 1 when
compared to healthy control fibroblast (C1 + C2) [(C) consists of a single experiment].
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FIGURE 2 | Mitochondrial stress test in TMEM126B patient fibroblasts. (A) Oxygen consumption rates (pMoles/min) measured in patient and healthy control
fibroblasts (C1) after 16 h treatment with 500 µM palmitic acid. (B) Maximal respiratory capacity in both control and patient fibroblasts increased with 21 and 25%,
respectively, upon treatment with palmitic acid, where respiration in the TMEM126B patient restored from 63 to 88% of the control level. (C) The measured increase
in maximal respiration resulted in a 45 and 67% increase in respiratory spare capacity in control and patient cells, respectively. (D) ATP production in patient
fibroblasts was 63% of the untreated control level and was not significantly altered by palmitic acid treatment. (E) Also proton leakage was not significantly changed,
where basal respiration due to non-coupled ATP production was never higher than 17%. ∗Statistically significant.
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FIGURE 3 | The effect of palmitic acid on the maximal respiratory capacity in
fibroblasts. Control (C1) and patient fibroblasts with defects in the complex I
subunit and assembly factor genes NDUFS7 (p.V122M), NDUFAF5 (p.L159F),
NDUFA12 (c.83dup, frameshift), NDUFV2 (p.A183T), and ACAD9 (p.R532W)
were treated with palmitic acid prior to seahorse analysis. NDUFS7 and
NDUFAF5 cells were responsive to palmitic acid as a significant increase of,
respectively, 32 and 22% in maximal respiratory capacity was measured. No
significant changes in maximal respiration were measured in NDUFA12,
NDUFV2, and ACAD9 defective fibroblasts. ∗Statistically significant.
Mitochondrial Respiration and
Fatty-Acid Treatment
A mitochondrial stress test was performed to examine OXPHOS
capacity in patient fibroblasts. OCR measurements indicated
decreased ATP production and decreased maximum respiratory
capacity in patient fibroblast compared to control lines (C1
and C2) (Supplementary Figure S4A). As indicated by the
extracellular acidification rates (ECAR), patient fibroblasts
were more dependent on glycolytic metabolism than control
fibroblasts (Supplementary Figure S4B). Respiratory findings
therefore corresponded with the observed complex I assembly
defect in the patient’s fibroblasts. To test if unsaturated or
saturated fatty acids have an effect on OXPHOS capacity, patient
fibroblasts were treated with 500 µM oleic acid or palmitic
acid, respectively, for 16 h prior to measuring the oxygen
consumption under different mitochondrial stress conditions.
Whereas oleic acid did not have any significant effect on the
OCR in patient or control cells (C1) (Supplementary Figure
S5), pre-incubation with palmitic acid resulted in a significant
increase of 25% in maximal respiratory capacity in TMEM126B
patient fibroblasts, from 63 to 88% of the untreated control level
(Figures 2A,B). In control fibroblasts, palmitic acid treatment
significantly increased maximal respiratory capacity with 21%.
This increase in maximal respiration was accompanied by an
increase in respiratory spare capacity of 45 and 67% in control
and patient cells, respectively (Figure 2C). ATP production in
patient fibroblasts was 63% of the untreated control condition
and increased 10% as a result of palmitic acid treatment,
however, this was not statistically significant (Figure 2D). Proton
leakage was not significantly changed, where basal respiration
due to non-coupled ATP production was never higher than 17%
(Figure 2E).
To test if the increase in maximal respiratory capacity after
palmitic acid treatment in control and TMEM126B patient
fibroblasts (p.G212V) was related to complex I function in
general, we performed similar respiratory measurements
in patient fibroblasts with a variety of complex I gene
defects, all patients being CI deficient in muscle biopsy, but
not all of them with a significant respiratory deficiency in
FIGURE 4 | TMEM126B functions as an early complex I assembly factor. TMEM126B is required for the joining of the ∼315 and ∼370 kDa assembly intermediates
(previously estimated ∼400 and ∼460 kDa, respectively). BN-Page on TMEM126B defective patient fibroblasts indicated accumulation of NDUFA5 (Q-module) in the
∼315 kDa intermediate and a drastic decrease in complex I, indicating that part of the peripheral arm was missing. Membrane arm subunit NDUFB8 (N-module) was
present in normal quantities in mature complex I, indicating that assembly of the complex I membrane arm succeeded despite missing parts of the peripheral arm.
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fibroblasts (Figure 3). This included patients with mutations
in the subunits NDUFS7 (p.V122M), NDUFA12 (c.83dup,
frameshift), NDUFV2 (p.A183T) and assembly factors
ACAD9 (p.R532W) and NDUFAF5 (p.L159F). As indicated
in Figure 3 and Supplementary Figure S6, fibroblast with
pathogenic mutations in NDUFS7 and NDUFAF5 showed
a significant increase of 32% (from 63 to 83% of untreated
control) and 22% (from 107 to 131% of untreated control),
respectively, in maximal respiratory capacity upon palmitic acid
treatment. No significant influence of palmitic acid on maximal
respiration was measured in the NDUFA12 (71% of control),
NDUFV2 (75% of control), and ACAD9 (70% of control)
fibroblasts.
DISCUSSION
Dietary studies in a complex I deficient patient with exercise
intolerance indicated beneficial effects of a high-fat diet on the
patient’s muscle endurance. WES analysis was performed to
characterize the genetic defect and identified a highly damaging,
homozygous p.G212V substitution in the transmembrane region
of TMEM126B (NM_018480.4:c.635G > T). Our data show that
the p.G212V mutation in TMEM126B causes an accumulation
of the 315 kDa complex, containing the peripheral arm subunit
NDUFA5 (Cx Iα), possibly via interrupted merging of the
315 and 370 kDa subcomplexes (Figure 4). This resulted
in a drastic loss of mature complex I in patient fibroblasts.
The resulting complex I deficiency could be rescued by wild-
type TMEM126B, confirming causality. Last year, the first
patients with TMEM126B defects were identified, all carrying the
p.G212V mutation in hetero- or homozygous fashion (Alston
et al., 2016; Sanchez-Caballero et al., 2016), possibly due to
the relatively high allele frequency in the European-American
population (0.1–0.2%). Our data show that biochemical and
clinical differences exist among the homozygous p.G212V
patients (Table 2). In line with the complex I deficiency described
for subject 6 of the previously reported cases (Alston et al.,
2016), we observed a respiratory deficiency in the patient’s
fibroblasts. In contrast, the second case, subject 1, showed a
muscle specific respiratory deficiency. Clinical symptoms in our
patient were similar to subject 1, as both manifested with mild
exercise intolerance (Table 2). In contrast, the other reported case
suffered from more severe, heterogeneous symptoms, involving
cardiomyopathy, renal failure and growth deficits. Yet, it is
most likely that the p.G212V substitution explains a relatively
mild phenotype, as all other reported TMEM126B patients
were described to suffer mainly from exercise intolerance,
even in combination with more harmful nonsense mutations.
Most likely, in our opinion, the TMEM126B mutation by itself
cannot explain the extended phenotype of the severely affected
patient.
Considerable differences in complex I assembly were
observed in TMEM126B patients (Table 3). Where our data
indicated that an incomplete constitution of complex I affected
mitochondrial respiration in both muscle and fibroblasts, a
previously reported homozygous p.G212V patient did not show
an assembly defect in fibroblasts at all. Subunits from both
the early ∼315 kDa peripheral arm intermediate (NDUFA9,
NDUFS3; Q-module) and the ∼370 kDa membrane arm
(NDUFB6; P-module) were present in mature complex I in
normal quantities. In contrast, complex I in muscle tissue
showed an almost complete lack of the membrane arm
subunit NDUFB8 (∼650 kDa intermediate), likely indicating
a decrease in the total amount of mature complex I (Tabel 3
and Figure 4). The p.G212V mutation in combination with
more harmful nonsense and splice mutations was shown
to cause a decrease in total amount of mature complex
I, as subunits of the peripheral arm (NDUFS3, NDUFA9)
and membrane arm were significantly decreased (NDUFB8,
NDUFA13, and NDUFB6) (McKenzie and Ryan, 2010; Mimaki
et al., 2012). This is striking as the severity of the assembly
defect is apparently not defined by the mildest mutation.
As shown in Figure 4, the current complex I assembly
model is suggested to start with the joining of a ∼315 kDa
subcomplex, containing the peripheral arm subunit NDUFA5
(Q-module, Cx Iα), and a ∼370 kDa subcomplex, containing
the membrane arm subunit NDUFB8 (N-module, Cx Iβ)
(previously estimated ∼400 and ∼460 kDa, respectively)
(Lazarou et al., 2009; Mimaki et al., 2012; Andrews et al.,
2013; Rhein et al., 2016). The MCIA complex, containing
TMEM126B, was found to be associated with the ∼370 kDa
assembly intermediate. siRNA-knockdown experiments in
human 143B cells confirmed a role for TMEM126B as an
early extrinsic assembly factor as a significant loss of the
peripheral arm subunit NDUFA5 in complex I occurred
together with an accumulation of the ∼315 kDa subcomplex
(Andrews et al., 2013). Membrane arm subunit NDUFB8
revealed elevated levels of the ∼370 kDa subcomplex and
decreased amounts of the larger ∼550 kDa intermediate,
suggesting that TMEM126B is required for the joining of the
∼315 and ∼370 kDa subcomplexes during early complex
I assembly. Yet, as NDUFB8 was still abundant in mature
complex I, it is likely that part of the membrane arm assembly
succeeded.
Our patient showed improved muscle endurance and strength
on a high-fat diet compared to a high carbohydrate diet. For
the clinical benefits of high-fat intake in complex I deficiency
anecdotic reports exist and have led to the clinical use of
different therapeutic high-fat diets and ketogenic diets (low
in carbohydrates). Not all complex I deficient patients seem
to benefit from such diet, but it is currently unclear which
complex I gene defects respond to these therapies and how
mitochondrial function is influenced by an increase in fatty-
acids or ketone bodies. FFAs are an important source for
mitochondrial energy production, but it has been difficult to
elucidate their effect on mitochondrial function as contradictory
effects have been reported in terms of mitochondrial oxygen
consumption and toxicity (Hirabara et al., 2006; Maassen et al.,
2007; Abe et al., 2013). In line with mitochondrial respiration data
from mouse podocytes, mouse neonatal myocytes and Normal
Human Dermal Fibroblasts (NHDF), we measured a significant
increase in oxygen consumption of healthy control fibroblasts
(NHDF) due to palmitic acid treatment (Zhang et al., 2012;
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Abe et al., 2013; Pfleger et al., 2015). Maximal mitochondrial
respiration capacity and spare capacity significantly increased
with palmitic acid. Besides the maximal respiratory capacity, the
spare mitochondrial respiratory capacity (or reserve capacity) has
been reported as an important part of mitochondrial function,
especially when cells are subject to stress, demanding increased
levels of ATP to maintain cellular functions. Improvements in
spare respiratory capacity can lead to increased ATP production
to overcome stress and enhance cell viability, where complex II
was suggested to be an important source of this reserve capacity
TABLE 2 | Clinical and biochemical characteristics of the homozygous p.G212V TMEM126B patients.
Patient Mutation Clinic Muscle
morphology
Muscle CI activity Fibroblast
OXPHOS
CI assembly
Index patient
Non-consanguineous
Homozygous
pG212V
Exercise
intolerance (mild)
Subsarcolemmal
accumulation
mitochondria, RRF
CI↓ (C1: 21%, as to
control SEM)
OXHOS capacity
(OCR)↓
Incomplete
assembly of CI,
part of peripheral
arm missing
Subject 1
Non-consanguineous
(Alston et al., 2016)
Homozygous
pG212V
Exercise
intolerance (mild)
Subsarcolemmal
accumulation
mitochondria, RRF
CI↓ (C1: 36%, as to
control SEM)
CI activity (normal) Fibroblasts: no
assembly defect;
muscle: complete
lack of mature CI or
membrane arm
module
Subject 6
Non-consanguineous
(Alston et al., 2016)
Homozygous
pG212V
Gastroesophageal
reflux, renal failure,
cardiomyopathy,
failure to thrive,
growth deficits
Subsarcolemmal
accumulation
mitochondria, RRF
CI↓ (C1: 17%, as to
control SEM)
CI activity↓ n.d.
TABLE 3 | The effect of homozygous and compound heterozygous p.G212V TMEM126B mutations on complex I assembly.
Homozygous patients Mutation Peripheral arm
subunits present in
early 315–400 kDa
intermediates
(fibroblasts)
Membrane arm
subunits present in
>370–460 kDa
intermediates
(fibroblasts)
Muscle BN-PAGE
Index patient pG212V NDUFA5↓ NDUFB8 (normal) n.d.
Subject 1
(Alston et al., 2016)
pG212V NDUFA9 (normal),
NDUFS3 (normal)
NDUFB6 (normal) NDUFB8↓
(∼370 kDa membrane
arm intermediate)
Heterozygous patients
Subject 1 + 3
(Sanchez-Caballero et al., 2016)
pG212V; pAsp133Asn (splice variant) NDUFS3↓ +
accumulation small
subcomplexes
NDUFB8↓, NDUFA13↓ n.d.
Subject 2
(Sanchez-Caballero et al., 2016)
pG212V; pGln70∗(nonsense) n.d. NDUFB8↓, NDUFA13↓ n.d.
Subject 2 + 3
(Alston et al., 2016)
pG212V; pAsn134Ilefs∗2 (nonsense) NDUFA9↓, NDUFS3↓ NDUFB6↓ n.d.
TABLE 4 | The effect of palmitic acid on respiratory capacity in patient fibroblasts with different CI defects.
Complex I defect Patient clinic M/F complex I activity OXPHOS deficiency
on seahorse (F)
Significant effect of
palmitic acid on max.
resp.
Healthy control (NHDF) n.a. Normal No Yes (20–21% increase)
TMEM126B: p.G212V (c.635G > T) substitution Exercise intolerance M: CI = 21% Yes Yes (25% increase)
NDUFS7: p.V122M (c.364G > A) substitution Leigh M: CI = 37% (mild decrease CIII) Yes Yes (32% increase)
NDUFAF5: p.Leu159Phe (c.477A > C) substitution Leigh M: CI = 32% No Yes (22% increase)
NDUFA12: homozygous c.83dup, frameshift Leigh M: CI = 16%, F: CI = 47% Yes No
ACAD9: p.Arg532Tryp (c.1594C > T) substitution Exercise intolerance, fatigue M: CI = 30%, F: CI = 50% Yes No
NDUFV2: p.Ala183Thr (c.547G > A) substitution White matter degeneration M: CI = 47% Yes No
“Blue” colored row = assembly factor defect, “gray” colored row = subunit defect, M = muscle, F = fibroblast.
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(Pfleger et al., 2015; Yamamoto et al., 2016). As there have been
indications that long-chain fatty acid can increase proton leak
in liver mitochondria, possibly via mitochondrial uncoupling
by the ATP/ADP and aspartate/glutamate antiporters, we have
assessed whether this mito-toxic effect also occurred during
our respiratory assay. We measured no significant increase in
proton leakage due to palmitic acid treatment in the fibroblasts,
which could otherwise have influenced the measured maximal
respiratory levels (Samartsev et al., 1997; Hirabara et al.,
2006).
Our data show that, despite the severe complex I assembly
defect, maximal mitochondrial respiration and spare capacity in
TMEM126B defective patient cells significantly improved due
to palmitic acid treatment (up to 88% of untreated control
level), therewith supporting the dietary intervention studies
in this patient. Interestingly, the unsaturated fatty acid oleic
acid did not have any effect on mitochondrial respiration.
The same assay was used for testing patient fibroblasts with
different complex I defects, affecting both subunits and assembly
factors, and showed that only part of the complex I defects
are responsive to palmitic acid treatment, including NDUFS7
and NDUFAF5 defects. We demonstrate that this is an easy
assay, which could be used as a personal medicine tool in
the clinic to discriminate complex I deficient patients who
might benefit from the intake of palmitic-acid, and those who
could not (Golubitzky et al., 2011). In line with the current
knowledge on FFAs, we show that the effects strongly differ
among the individual FFAs, as the unsaturated FFA oleic acid
did not have any effect on mitochondrial respiration at all.
Whereas in clinical practice, different diets are subsequently
tested in the patient, without knowing the effective components,
our cell-line assay could overcome these limitations as a
tool to identify responsiveness to specific FFAs (or other
nutrients or drugs), thereby providing a personalized treatment
approach. Although, therapeutic high-fat diets could be a possible
way to increase the intake of palmitic acid in responsive
patients, one should be aware that individual FFAs could
behave differently as part of a complete diet (Watt et al.,
2012).
It is difficult to fully explain mechanistically the differences
in reaction by the data available. A proposed mechanism
for FFAs on mitochondrial function involved the induction
of the PPARγ pathway. The saturated FFAs deconoic acid
and palmitic acid, but not the unsaturated FFA oleic acid,
were previously shown to increase PPARγ protein expression
or, as an agonist, stimulate its activity. PPARγ can stimulate
mitochondrial biogenesis and proliferation, and could therefore
increase cellular respiratory capacity (Miglio et al., 2009; Hughes
et al., 2014; Kanabus et al., 2016). However, this would be a
general effect, suggesting that this mechanism cannot explain
the differences between the patients, because it would imply that
all CI deficient patients in our assay should have reacted to the
treatment, independent of the assembly defect. An alternative
explanation could be an increase in FFA beta-oxidation, which
results in relatively higher FADH2:NADH ratio’s (1:1) than
glycolysis (1:3). As FADH2 can directly donate its electrons
to complex II of the OXPHOS system, it could bypass the
complex I defect, therewith improving mitochondrial respiration
(Roef et al., 2002; Paoli et al., 2014; Steriade et al., 2014).
Although the latter mechanism might contribute to an increase
in respiratory capacity, this cannot explain our observation
that only part of the complex I defects responds to palmitic
acid treatment (Table 4). Complex I specific effects have
previously been reported for both FFA’s and ketone bodies,
where decanoic acid was shown to increase complex I activity
in healthy neuronal cells (Hughes et al., 2014), and ketone
bodies were shown to alleviate mitochondrial dysfunction by
increasing complex I activity in MELAS cells (neuronal cybrid
cells with m.3243A > G) via restoration of the complex I
assembly defect (Frey et al., 2017). Interestingly, we found
genetic defects in assembly factors and subunit (NDUFAF5,
NDUFS7, and TMEM126B) involved in early assembly of the
peripheral arm of complex I responsive to palmitic acid (Table 4)
(Mimaki et al., 2012; Rhein et al., 2016). Although ACAD9,
which is functional in the same MCIA complex as TMEM126B,
did not respond to the treatment, this protein is known to
have another crucial function as a catalyzer in the fatty acid
beta-oxidation (McAndrew et al., 2008), making its role more
complicated. The non-responsive gene defects affecting the
subunits NDUFA12 and NDUFV2 are incorporated at a later
assembly stage (>800 kDa) (Mimaki et al., 2012), suggesting
a compensating role for FFA in the early assembly process.
However, current data is still too limited to draw a definite
conclusion on the mechanism and testing more complex I defects
will be needed.
Our data shows at a biochemical level that palmitic acid
intake, possibly also as part of a therapeutic high fat diet,
can be beneficial for patients with a defect in assembly factor
TMEM126B and that our cell line assay will be a useful approach
for the selection of patients, who might potentially benefit from
this therapeutic diet. It is obvious that this cell line assay could
also be extended to test responsiveness of patients to other
nutrients and drugs, using mitochondrial respiration as outcome
measure.
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